Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 09 04 2020
accepted: 18 06 2020
entrez: 2 7 2020
pubmed: 2 7 2020
medline: 15 9 2020
Statut: epublish

Résumé

Diabetes mellitus is a well-known risk factor for pancreatic cancer. We focused on hyperglycemia, a main feature of diabetes mellitus, and uncovered its effect on precancerous pancreatic intraepithelial neoplasia (PanIN) progression. In vivo induction of hyperglycemia with 100 mg/kg streptozotocin in KrasLSL G12D Pdx1Cre (KP) mice promoted the PanIN formation and progression. Preconditioning with a high- or low-glucose medium for 28 days showed that a high-glucose environment increased cell viability and sphere formation in PANC-1, a Kras-mutant human pancreatic ductal adenocarcinoma cell line, and mPKC1, a Kras-mutant murine pancreatic cancer cell line. In contrast, no changes were observed in BxPC3, a Kras-wild-type human pancreatic cancer cell line. Orthotopic injection of mPKC1 into the pancreatic tails of BL6/J mice showed that cells maintained in high-glucose medium grew into larger tumors than did those maintained in low-glucose medium. Hyperglycemia strengthened the STAT3 phosphorylation, which was accompanied by elevated MYC expression in Kras-mutant cells. Immunohistochemistry showed stronger phosphorylated STAT3 (pSTAT3) and MYC staining in PanINs from diabetic KP mice than in those from euglycemic counterparts. STAT3 inhibition with 1 μM STAT3 inhibitor STATTIC in Kras-mutant pancreatic cell lines blocked the cell viability- and sphere formation-enhancing effects of the hyperglycemic environment and reversed the elevated pSTAT3 and MYC expression. MYC knockdown did not affect cell viability but did reduce sphere formation. No decrease in pSTAT3 expression was observed upon siMYC treatment. In conclusion, hyperglycemia, on a Kras-mutant background, aggravates the PanIN progression, which is accompanied by elevated pSTAT3 and MYC expression.

Identifiants

pubmed: 32609742
doi: 10.1371/journal.pone.0235573
pii: PONE-D-20-10172
pmc: PMC7329089
doi:

Substances chimiques

KRAS protein, human 0
MYC protein, human 0
Proto-Oncogene Proteins c-myc 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0235573

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Gastroenterology. 2013 Dec;145(6):1449-58
pubmed: 23958541
Gastroenterology. 2009 Aug;137(2):482-8
pubmed: 19375425
Cancer Cell. 2007 Mar;11(3):291-302
pubmed: 17349585
Cell. 1988 May 20;53(4):549-54
pubmed: 2453289
Oncol Rep. 2011 May;25(5):1279-87
pubmed: 21249318
JAMA. 2005 Dec 14;294(22):2872-8
pubmed: 16352795
Gut. 2002 Dec;51(6):849-52
pubmed: 12427788
Genes Dev. 2003 Dec 15;17(24):3112-26
pubmed: 14681207
Cancer Res. 2018 Nov 1;78(21):6235-6246
pubmed: 30154150
Genes Dev. 2000 Oct 1;14(19):2501-14
pubmed: 11018017
J Diabetes Complications. 2016 Nov - Dec;30(8):1426-1433
pubmed: 27481368
Br J Cancer. 2005 Nov 28;93(11):1310-5
pubmed: 16288300
Gastroenterology. 2004 Jul;127(1):250-60
pubmed: 15236190
Oncotarget. 2017 Sep 16;8(53):91516-91529
pubmed: 29207662
Mol Med Rep. 2018 Jan;17(1):1311-1320
pubmed: 29115516
Nat Commun. 2017 Nov 23;8(1):1728
pubmed: 29170413
Nature. 2017 Feb 16;542(7641):362-366
pubmed: 28178232
J Cell Biochem. 2018 Nov 11;:
pubmed: 30417413
Oncotarget. 2015 Oct 13;6(31):31119-33
pubmed: 26439801
Eur J Cancer. 2011 Sep;47(13):1928-37
pubmed: 21458985
Br J Cancer. 2007 Feb 12;96(3):507-9
pubmed: 17224924
PLoS One. 2015 Jul 29;10(7):e0134321
pubmed: 26222906
Cancer Prev Res (Phila). 2013 Oct;6(10):1064-73
pubmed: 23943783
JAMA. 2009 Jun 24;301(24):2553-62
pubmed: 19549972
J Diabetes Res. 2015;2015:962383
pubmed: 26421309
Gastroenterology. 2018 Aug;155(2):490-500.e2
pubmed: 29723506
Sci Rep. 2014 Oct 23;4:6747
pubmed: 25339498
Biomed Pharmacother. 2017 Dec;96:1094-1102
pubmed: 29174036
Cell Mol Gastroenterol Hepatol. 2018 Jul 26;6(4):429-449
pubmed: 30258965
Nature. 2014 Jul 24;511(7510):483-7
pubmed: 25043018
Pancreas. 2015 Jul;44(5):693-712
pubmed: 25931254
Cancer Res. 2011 Jul 15;71(14):5020-9
pubmed: 21586612
Gastroenterology. 2008 Jan;134(1):95-101
pubmed: 18061176
J Gastroenterol. 2013 Feb;48(2):238-46
pubmed: 22735942

Auteurs

Katsuhiko Sato (K)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Hayato Hikita (H)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Yuta Myojin (Y)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Kenji Fukumoto (K)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Kazuhiro Murai (K)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Sadatsugu Sakane (S)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Takeshi Tamura (T)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Takuo Yamai (T)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Yasutoshi Nozaki (Y)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Teppei Yoshioka (T)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Takahiro Kodama (T)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Minoru Shigekawa (M)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Ryotaro Sakamori (R)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Tomohide Tatsumi (T)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Tetsuo Takehara (T)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH